EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer

Ze-Wei Cheng, Meng Wei, Yuan Zhang, Yi-Ze Liang, Wei-Bo Cao, Ru-Dong Zhao, Zhi-Bo Yan, Guo-Rui Sun, Xiao-Han Cui, Wen-Bin Yu

World Journal of Gastroenterology · 2027-01-14 · 33 (2)

DOI: 10.3748/wjg.122397 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND Neoadjuvant chemotherapy remains the standard for locally advanced gastric cancer (LAGC), yet outcomes remain suboptimal. Programmed cell death protein-1 inhibitors and apatinib have been used individually with chemotherapy for the treatment of LAGC, but the clinical benefit of programmed cell death protein-1 inhibitors plus apatinib and chemotherapy (PAC) as a neoadjuvant strategy requires comprehensive evaluation. AIM To evaluate the surgical safety and efficacy of PAC vs preoperative chemotherapy for LAGC. METHODS This retrospective study included 292 patients with LAGC who received either PAC (n = 92) or preoperative chemotherapy (n = 200) followed by radical gastrectomy between January 2019 and December 2022. Tumor regression, surgical outcomes, postoperative recovery, and survival were compared between groups. Subgroup analysis was performed to evaluate the role of indocyanine green (ICG) fluorescence guidance. Overall survival, progression-free survival, and disease-free survival were estimated using Kaplan-Meier method, and independent prognostic factors were identified by the Cox proportional hazards regression model. RESULTS The PAC group demonstrated significantly higher pathological complete response rates (28.3% vs 6.5%, P < 0.001) and major pathological response rates (45.7% vs 27.5%, P = 0.002). Despite the PAC regimen increased intraoperative blood loss (100 mL vs 80 mL, P < 0.001), R0 resection rates (92.4% vs 91.0%, P = 0.693) and postoperative complications (23.9% vs 28.0%, P = 0.463) were comparable. ICG fluorescence guidance in the PAC group reduced the open conversion rate (0% vs 19.4%, P = 0.015) and increased the lymph node yield (32 vs 24, P = 0.004). The PAC regimen was significantly associated with prolonged survival outcomes (log-rank P < 0.001) and was an independent prognostic predictor in multivariate analyses (P < 0.05). CONCLUSION The PAC regimen significantly improved the pathological response and survival of patients with LAGC, without compromising surgical safety. ICG fluorescence guidance along with the PAC regimen may further optimize surgical outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →